Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1991 Sep;155(3):293–296.

Cardiomyopathy associated with high-dose interleukin-2 therapy.

A C Beck 1, J H Ward 1, E H Hammond 1, R B Wray 1, W E Samlowski 1
PMCID: PMC1002997  PMID: 1949788

Full text

PDF
293

Images in this article

294Image
on p.294
295Image
on p.295

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cuturi M. C., Anegón I., Sherman F., Loudon R., Clark S. C., Perussia B., Trinchieri G. Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med. 1989 Feb 1;169(2):569–583. doi: 10.1084/jem.169.2.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dutcher J. P., Creekmore S., Weiss G. R., Margolin K., Markowitz A. B., Roper M., Parkinson D., Ciobanu N., Fisher R. I., Boldt D. H. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol. 1989 Apr;7(4):477–485. doi: 10.1200/JCO.1989.7.4.477. [DOI] [PubMed] [Google Scholar]
  3. Gaynor E. R., Vitek L., Sticklin L., Creekmore S. P., Ferraro M. E., Thomas J. X., Jr, Fisher S. G., Fisher R. I. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1988 Dec 15;109(12):953–958. doi: 10.7326/0003-4819-109-12-953. [DOI] [PubMed] [Google Scholar]
  4. Gemlo B. T., Palladino M. A., Jr, Jaffe H. S., Espevik T. P., Rayner A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Oct 15;48(20):5864–5867. [PubMed] [Google Scholar]
  5. Gravanis M. B., Ansari A. A. Idiopathic cardiomyopathies. A review of pathologic studies and mechanisms of pathogenesis. Arch Pathol Lab Med. 1987 Oct;111(10):915–929. [PubMed] [Google Scholar]
  6. Hegewisch S., Weh H. J., Hossfeld D. K. TNF-induced cardiomyopathy. Lancet. 1990 Feb 3;335(8684):294–295. doi: 10.1016/0140-6736(90)90115-l. [DOI] [PubMed] [Google Scholar]
  7. Kragel A. H., Travis W. D., Feinberg L., Pittaluga S., Striker L. M., Roberts W. C., Lotze M. T., Yang J. J., Rosenberg S. A. Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients. Hum Pathol. 1990 May;21(5):493–502. doi: 10.1016/0046-8177(90)90005-p. [DOI] [PubMed] [Google Scholar]
  8. Lee R. E., Lotze M. T., Skibber J. M., Tucker E., Bonow R. O., Ognibene F. P., Carrasquillo J. A., Shelhamer J. H., Parrillo J. E., Rosenberg S. A. Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol. 1989 Jan;7(1):7–20. doi: 10.1200/JCO.1989.7.1.7. [DOI] [PubMed] [Google Scholar]
  9. Lenk H., Tanneberger S., Müller U., Ebert J., Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1989;24(6):391–392. doi: 10.1007/BF00257449. [DOI] [PubMed] [Google Scholar]
  10. Lie J. T. Myocarditis and endomyocardial biopsy in unexplained heart failure: a diagnosis in search of a disease. Ann Intern Med. 1988 Oct 1;109(7):525–528. doi: 10.7326/0003-4819-109-7-525. [DOI] [PubMed] [Google Scholar]
  11. Margolin K. A., Rayner A. A., Hawkins M. J., Atkins M. B., Dutcher J. P., Fisher R. I., Weiss G. R., Doroshow J. H., Jaffe H. S., Roper M. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol. 1989 Apr;7(4):486–498. doi: 10.1200/JCO.1989.7.4.486. [DOI] [PubMed] [Google Scholar]
  12. Nora R., Abrams J. S., Tait N. S., Hiponia D. J., Silverman H. J. Myocardial toxic effects during recombinant interleukin-2 therapy. J Natl Cancer Inst. 1989 Jan 4;81(1):59–63. doi: 10.1093/jnci/81.1.59. [DOI] [PubMed] [Google Scholar]
  13. Ognibene F. P., Rosenberg S. A., Lotze M., Skibber J., Parker M. M., Shelhamer J. H., Parrillo J. E. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest. 1988 Oct;94(4):750–754. doi: 10.1378/chest.94.4.750. [DOI] [PubMed] [Google Scholar]
  14. Parker M. M., Parrillo J. E. Septic shock. Hemodynamics and pathogenesis. JAMA. 1983 Dec 23;250(24):3324–3327. [PubMed] [Google Scholar]
  15. Parrillo J. E., Burch C., Shelhamer J. H., Parker M. M., Natanson C., Schuette W. A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest. 1985 Oct;76(4):1539–1553. doi: 10.1172/JCI112135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Quesada J. R., Talpaz M., Rios A., Kurzrock R., Gutterman J. U. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986 Feb;4(2):234–243. doi: 10.1200/JCO.1986.4.2.234. [DOI] [PubMed] [Google Scholar]
  17. Rosenberg S. A., Lotze M. T., Muul L. M., Chang A. E., Avis F. P., Leitman S., Linehan W. M., Robertson C. N., Lee R. E., Rubin J. T. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897. doi: 10.1056/NEJM198704093161501. [DOI] [PubMed] [Google Scholar]
  18. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rosenberg S. A., Lotze M. T., Yang J. C., Linehan W. M., Seipp C., Calabro S., Karp S. E., Sherry R. M., Steinberg S., White D. E. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989 Dec;7(12):1863–1874. doi: 10.1200/JCO.1989.7.12.1863. [DOI] [PubMed] [Google Scholar]
  20. Samlowski W. E., Ward J. H., Craven C. M., Freedman R. A. Severe myocarditis following high-dose interleukin-2 administration. Arch Pathol Lab Med. 1989 Aug;113(8):838–841. [PubMed] [Google Scholar]
  21. Schuchter L. M., Hendricks C. B., Holland K. H., Shelton B. K., Hutchins G. M., Baughman K. L., Ettinger D. S. Eosinophilic myocarditis associated with high-dose interleukin-2 therapy. Am J Med. 1990 Apr;88(4):439–440. doi: 10.1016/0002-9343(90)90507-a. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES